A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials. [Review]

MedStar author(s):
Citation: Diabetes, Obesity & Metabolism. 20 Suppl 1:22-33, 2018 02.PMID: 29364586Institution: MedStar Health Research InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Diabetes Mellitus/dt [Drug Therapy] | *Glucagon-Like Peptide-1 Receptor/ag [Agonists] | *Hypoglycemic Agents/tu [Therapeutic Use] | Clinical Trials, Phase III as Topic | Glucagon-Like Peptide 1/aa [Analogs & Derivatives] | Glucagon-Like Peptide 1/tu [Therapeutic Use] | Glucagon-Like Peptides/aa [Analogs & Derivatives] | Glucagon-Like Peptides/tu [Therapeutic Use] | Humans | Immunoglobulin Fc Fragments/tu [Therapeutic Use] | Liraglutide/tu [Therapeutic Use] | Peptides/tu [Therapeutic Use] | Randomized Controlled Trials as Topic | Recombinant Fusion Proteins/tu [Therapeutic Use] | Treatment Outcome | Weight Loss/de [Drug Effects]Year: 2018ISSN:
  • 1462-8902
Name of journal: Diabetes, obesity & metabolismAbstract: AIMS: To review the evolution and advancement of GLP-1 receptor agonist (GLP-1RA) therapy, through the lens of randomised controlled trials, from differentiating characteristics, efficacy, safety, tolerability, and cardiovascular outcomes, to evidence gaps and next steps.CONCLUSIONS: Over a decade of clinical studies have established the unique contributions of GLP-1 RAs in the treatment of diabetes. Individual differences between the different GLP-1 RAs, in delivery, pharmacokinetic and clinical effects, exist, allowing for tailored approaches to clinical care. The strength of evidence generated through RCTs, both short-term and long-term studies, will continue to evolve and inform our current paradigms in diabetes care.Copyright (c) 2018 John Wiley & Sons Ltd.METHODS: Clinical review of published phase 3 or later RCT data studying efficacy, safety, and outcomes of approved GLP-1 RA therapies.RESULTS: Through a wealth of studies, including both placebo-controlled and active-controlled studies, GLP-1 RAs have demonstrated high glycemic efficacy and ability to facilitate weight loss, with minimal risk of hypoglycemia, potential to restore beta cell function, and evidence for improved cardiovascular outcomes in those at risk.All authors: Aroda VRFiscal year: FY2018Digital Object Identifier: ORCID: Date added to catalog: 2018-08-16
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 29364586 Available 29364586

AIMS: To review the evolution and advancement of GLP-1 receptor agonist (GLP-1RA) therapy, through the lens of randomised controlled trials, from differentiating characteristics, efficacy, safety, tolerability, and cardiovascular outcomes, to evidence gaps and next steps.

CONCLUSIONS: Over a decade of clinical studies have established the unique contributions of GLP-1 RAs in the treatment of diabetes. Individual differences between the different GLP-1 RAs, in delivery, pharmacokinetic and clinical effects, exist, allowing for tailored approaches to clinical care. The strength of evidence generated through RCTs, both short-term and long-term studies, will continue to evolve and inform our current paradigms in diabetes care.

Copyright (c) 2018 John Wiley & Sons Ltd.

METHODS: Clinical review of published phase 3 or later RCT data studying efficacy, safety, and outcomes of approved GLP-1 RA therapies.

RESULTS: Through a wealth of studies, including both placebo-controlled and active-controlled studies, GLP-1 RAs have demonstrated high glycemic efficacy and ability to facilitate weight loss, with minimal risk of hypoglycemia, potential to restore beta cell function, and evidence for improved cardiovascular outcomes in those at risk.

English

Powered by Koha